119 related articles for article (PubMed ID: 21817195)
1. Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections.
Fuehner T; Dierich M; Duesberg C; DeWall C; Welte T; Haverich A; Warnecke G; Simon AR; Gottlieb J
Antivir Ther; 2011; 16(5):733-40. PubMed ID: 21817195
[TBL] [Abstract][Full Text] [Related]
2. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients.
Liu V; Dhillon GS; Weill D
Transpl Infect Dis; 2010 Feb; 12(1):38-44. PubMed ID: 19761558
[TBL] [Abstract][Full Text] [Related]
3. Paramyxovirus infection in lung transplant recipients.
Wendt CH; Fox JM; Hertz MI
J Heart Lung Transplant; 1995; 14(3):479-85. PubMed ID: 7654733
[TBL] [Abstract][Full Text] [Related]
4. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation.
Li L; Avery R; Budev M; Mossad S; Danziger-Isakov L
J Heart Lung Transplant; 2012 Aug; 31(8):839-44. PubMed ID: 22621746
[TBL] [Abstract][Full Text] [Related]
5. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation.
Glanville AR; Scott AI; Morton JM; Aboyoun CL; Plit ML; Carter IW; Malouf MA
J Heart Lung Transplant; 2005 Dec; 24(12):2114-9. PubMed ID: 16364859
[TBL] [Abstract][Full Text] [Related]
6. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study.
Gottlieb J; Schulz TF; Welte T; Fuehner T; Dierich M; Simon AR; Engelmann I
Transplantation; 2009 May; 87(10):1530-7. PubMed ID: 19461490
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin.
McCurdy LH; Milstone A; Dummer S
J Heart Lung Transplant; 2003 Jul; 22(7):745-53. PubMed ID: 12873542
[TBL] [Abstract][Full Text] [Related]
8. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients.
Kumar D; Husain S; Chen MH; Moussa G; Himsworth D; Manuel O; Studer S; Pakstis D; McCurry K; Doucette K; Pilewski J; Janeczko R; Humar A
Transplantation; 2010 Apr; 89(8):1028-33. PubMed ID: 20075787
[TBL] [Abstract][Full Text] [Related]
9. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis.
Gottlieb J; Mattner F; Weissbrodt H; Dierich M; Fuehner T; Strueber M; Simon A; Welte T
Respir Med; 2009 May; 103(5):743-9. PubMed ID: 19117741
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes of Paramyxovirus Infections in Lung Transplant Recipients Treated With Oral Ribavirin: A Two-Center Case Series.
Garcia B; Sharma N; Johnson K; Salgado J; Wille K
Exp Clin Transplant; 2019 Jun; 17(3):393-397. PubMed ID: 29108516
[TBL] [Abstract][Full Text] [Related]
11. Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study.
Chakrabarti S; Collingham KE; Holder K; Fegan CD; Osman H; Milligan DW
Bone Marrow Transplant; 2001 Oct; 28(8):759-63. PubMed ID: 11781627
[TBL] [Abstract][Full Text] [Related]
12. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome.
Avetisyan G; Mattsson J; Sparrelid E; Ljungman P
Transplantation; 2009 Nov; 88(10):1222-6. PubMed ID: 19935377
[TBL] [Abstract][Full Text] [Related]
14. Human metapneumovirus in lung transplant recipients: characteristics and outcomes.
Niggli F; Huber LC; Benden C; Schuurmans MM
Infect Dis (Lond); 2016; 48(11-12):852-6. PubMed ID: 27385394
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant baseline FEV1 and the development of bronchiolitis obliterans syndrome: an important confounder?
Burton CM; Iversen M; Mortensen J; Carlsen J; Andersen CB; Milman N; Scheike T
J Heart Lung Transplant; 2007 Nov; 26(11):1127-34. PubMed ID: 18022078
[TBL] [Abstract][Full Text] [Related]
16. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients.
Soghikian MV; Valentine VG; Berry GJ; Patel HR; Robbins RC; Theodore J
J Heart Lung Transplant; 1996 Sep; 15(9):881-7. PubMed ID: 8889983
[TBL] [Abstract][Full Text] [Related]
17. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.
Ruttmann E; Geltner C; Bucher B; Ulmer H; Höfer D; Hangler HB; Semsroth S; Margreiter R; Laufer G; Müller LC
Transplantation; 2006 May; 81(10):1415-20. PubMed ID: 16732179
[TBL] [Abstract][Full Text] [Related]
18. Infections in lung allograft recipients: ganciclovir era.
Valentine VG; Bonvillain RW; Gupta MR; Lombard GA; LaPlace SG; Dhillon GS; Wang G
J Heart Lung Transplant; 2008 May; 27(5):528-35. PubMed ID: 18442719
[TBL] [Abstract][Full Text] [Related]
19. A single-season prospective study of respiratory viral infections in lung transplant recipients.
Milstone AP; Brumble LM; Barnes J; Estes W; Loyd JE; Pierson RN; Dummer S
Eur Respir J; 2006 Jul; 28(1):131-7. PubMed ID: 16510454
[TBL] [Abstract][Full Text] [Related]
20. The impact of cytolytic therapy on bronchiolitis obliterans syndrome.
Date H; Lynch JP; Sundaresan S; Patterson GA; Trulock EP
J Heart Lung Transplant; 1998 Sep; 17(9):869-75. PubMed ID: 9773858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
